Kira8 NEW
| Price | $89 | $213 | $322 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-27 |
Product Details
| Product Name: Kira8 | CAS No.: 1630086-20-2 |
| Purity: 99.52% | Supply Ability: 10g |
| Release date: 2026/07/27 |
Product Introduction
Bioactivity
| Name | Kira8 |
| Description | Kira8 (AMG-18) is a mono-selective IRE1α inhibitor that allosterically attenuates IRE1α RNase activity with an IC50 of 5.9 nM. |
| In vitro | Kira8 more effectively causes IRE1α-driven apoptosis in INS-1 cells than KIRA6 and also reverses XBP1 splicing promoted by GNF-2. Kira8 blocks IRE1α oligomerization and effectively inhibits IRE1α RNase activity against XBP1 and Ins2 RNAs. |
| In vivo | One week of treatment of pre-diabetic NODs mice with Kira8 (50 mg/kg; i.p.; once a day) causes obvious reductions in islet XBP1 splicing and TXNIP mRNAs. It also preserves Ins1/Ins2, BiP, and MANF mRNAs. Male Ins2+/Akita mice are injected i.p. with KIRA8 (50 mg/kg; daily; for 35 days), obviously reduction of hyperglycemia becomes apparent over several weeks. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : < 10 mg/mL (16.64 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. DMSO : 150 mg/mL (249.53 mM), Sonication is recommended. H2O : insoluble 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (16.64 mM), Solution. |
| Keywords | Kira-8 | Kira8 | Kira 8 | IRE1α RNase | IRE1α | IRE1 | Inositol requiring enzyme 1 | Inhibitor | inhibit | AMG18 | AMG 18 |
| Inhibitors Related | B I09 | Sunitinib | 6-Bromo-2-hydroxy-3-methoxybenzaldehyde | D-F07 | STF-083010 | Z4P | Sunitinib Malate | MKC8866 | APY29 | GSK2850163 (S enantiomer) | GSK2850163 | Toyocamycin |
| Related Compound Libraries | Bioactive Compound Library | Endoplasmic Reticulum Stress Compound Library | Kinase Inhibitor Library | Bioactive Compound Library Plus | Post-Translational Modification Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $89.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-07-27 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY